ReviewFrontiers in cell and developmental biology2025
Prominent protumoral cellular compartments of the tumor microenvironment in triple-negative breast cancer.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Helenalin: a multifaceted sesquiterpene lactone with diverse biological activities-an integrative pharmacological and computational evidence.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptor expression. This malignancy is often associated with a poor prognosis, early recurrence, and limited treatment options. The tumor microenvironment (TME) in TNBC plays a pivotal role in tumor progression, immune evasion, and therapeutic resistance. In recent years, an increasing body of evidence has highlighted the critical interactions between cancer cells and the components within the TME, including immune cells and soluble components. These interactions influence not only the biological behavior of the tumor but also its response to treatment. Exploring the complex interplay between tumor cells and immune components continues to inform the development of more effective therapeutic approaches. In this study, we provide a synopsis of advancements regarding the TME in TNBC. In light of different cellular compartments, we delineate multiscale interplays within the stroma-tumor symbiosis and highlight their antitumor functions and promising targeting strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.